Phio Pharmaceuticals Corp.
PHIONasdaq
$1.03
↑ +3.0%Jul 17 close · end-of-day
Price
1Y↓ -56.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$10.9M
Free Cash Flow (TTM)
-$10.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-66.4%
ROIC
—
Debt / Equity
—
Net Cash
$17.0M
Return 1Y
-57.6%
Company profile
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.
- CEO
- Geert C. PhD
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Massachusetts
- Website
- phiopharma.com
Management & directors
- Bitterman Robert JChairman, Pres. & CEO
- Carson Lisa CabottVP, Finance and Administration
Roles derived from SEC Form 4 filings.
Earnings
PHIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.8M | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M |
| Net income | -$8.8M | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M |
| Diluted EPS | — | -$12.43 | -$10.10 | -$46.76 | -$9.08 | — |
| Operating cash flow | -$8.8M | -$11.9M | -$12.1M | -$10.7M | -$7.1M | -$8.0M |
| Free cash flow | -$8.8M | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.9M | -$1.6M | -$1.7M | -$1.9M | -$2.3M | -$2.5M | -$2.5M | -$4.2M |
| Net income | -$1.8M | -$1.5M | -$1.6M | -$1.8M | -$2.2M | -$2.4M | -$2.4M | -$4.0M |
| Diluted EPS | -$3.62 | -$1.54 | -$3.45 | -$0.41 | -$0.45 | — | — | — |
| Operating cash flow | -$1.8M | -$2.0M | -$1.4M | -$1.3M | -$2.5M | -$2.1M | -$2.1M | -$4.0M |
| Free cash flow | -$1.8M | -$2.0M | -$1.4M | -$1.3M | -$2.5M | -$2.1M | -$2.1M | -$4.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 26, 2026
Jun 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-26 | Bitterman Robert J· Chairman, Pres. & CEO | Buy | 10,000 | $0.99 | $9,900.00 | filing |
| 2026-02-05 | Lockshin Curtis | Award | 16,600 | $0.00 | $0.00 | filing |
| 2026-02-05 | Freeman Jonathan E | Award | 16,600 | $0.00 | $0.00 | filing |
| 2026-02-05 | Deming David H | Award | 23,800 | $0.00 | $0.00 | filing |
| 2026-02-05 | Carson Lisa Cabott· Chief Financial Officer | Award | 47,000 | $0.00 | $0.00 | filing |
| 2026-02-05 | BRADFORD PATRICIA A | Award | 18,500 | $0.00 | $0.00 | filing |
| 2026-02-05 | Bitterman Robert J· Chairman, Pres. & CEO | Award | 120,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | Bitterman Robert J· Chairman, Pres. & CEO | Buy | 5,000 | $1.03 | $5,150.00 | filing |
| 2025-12-23 | Bitterman Robert J· Chairman, Pres. & CEO | Buy | 5,000 | $1.02 | $5,100.00 | filing |
| 2025-11-21 | Bitterman Robert J· Chairman, Pres. & CEO | Buy | 5,000 | $1.14 | $5,700.00 | filing |
| 2025-11-18 | Bitterman Robert J· Chairman, Pres. & CEO | Buy | 5,000 | $1.27 | $6,350.00 | filing |
| 2025-09-11 | Bitterman Robert J· Chairman, Pres. & CEO | Tax withholding | 4,111 | $2.32 | $9,537.52 | filing |
| 2025-09-11 | Deming David H | Award | 14,000 | $0.00 | $0.00 | filing |
| 2025-09-11 | Lockshin Curtis | Award | 16,200 | $0.00 | $0.00 | filing |
| 2025-09-11 | Freeman Jonathan E | Award | 14,700 | $0.00 | $0.00 | filing |
| 2025-09-11 | Ferrara Robert L | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-09-11 | Carson Lisa Cabott· VP, Finance and Administration | Award | 47,000 | $0.00 | $0.00 | filing |
| 2025-09-11 | BRADFORD PATRICIA A | Award | 18,800 | $0.00 | $0.00 | filing |
| 2025-09-11 | Ferrara Robert L | Award | 23,100 | $0.00 | $0.00 | filing |
| 2025-09-11 | Bitterman Robert J· Chairman, Pres. & CEO | Award | 250,000 | $0.00 | $0.00 | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.